This multicentre retrospective study evaluates the success rate, adverse events, and patient satisfaction related to additively manufactured subperiosteal jaw implants (AMSJI®) in the mandible. The study analyses data from 40 AMSJI® implants placed between 2017 and beginning of 2024 in 19 patients with severe mandibular atrophy (Cawood-Howell classes IV-VII). The findings reveal a high level of patient satisfaction, and a survival rate of 92.5 % after an average follow-up of 804 days (SD ± 540 days). The most common post-operative adverse events were immediate oedema and temporary infection, which were generally managed with chlorhexidine mouth rinses, antibiotics, and paracetamol. One implant showed increased mobility (movement exceeding 1 mm in any direction) at the time of evaluation. Two other implants were removed due to persistent infection and suppuration, with a third implant scheduled for removal. Patient satisfaction in general was high at the time of the interview, with an average OHIP-14 score of 6.68 (SD ± 7.99) and a NRS score of 51.26 (SD ± 7.63). Mucosal recession (both buccal and lingual) was noted around 13 implants (32.25%)
however, patients did not regard this as a functional or aesthetic concern. Within the limitations of a short-term follow-up period, AMSJI in the mandible shows promise as an effective option for rehabilitating patients with severe mandibular atrophy. Despite the positive results, longer-term follow-up is necessary to confirm the implant system's durability and performance over time.